Liver, Gallbladder & Pancreatic Health • ICD-10-CM K74.02
Hepatic fibrosis, advanced fibrosis
Audited by the DotMD AI Specialist Council
•
FDA DailyMed SPL: 2026-11-02 • ICD-10-CM K74.02 • 7 Linked .gov / PubMed Citations
•
Governance: Dr. Julian Sterling, MD, FACS (NPI #1376841536)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary
Hepatic fibrosis, advanced fibrosis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Hepatic fibrosis, advanced fibrosis (K74.02; Liver, Gallbladder & Pancreatic Health) utilize comprehensive hepatic panel [Hepatic fibrosis, advanced fibrosis K74.02] and objective Total Bilirubin & in Hepatic fibrosis, advanced fibrosis (K74.02: Albumin) targets (Bilirubin 0.2–1.2 mg/dL; Albumin >= 4.0 g/dL (K74.02)) to prevent progression and functional morbidity.
- 2 Real-world patient consensus: Mapped to Liver, Gallbladder & Pancreatic Health under ICD-10-CM K74.02 for Hepatic fibrosis, advanced fibrosis clinical workups.
- 3 Typical cash cost range: Clinicians assessing Hepatic fibrosis, advanced fibrosis focus on oxidative lipotoxicity [Hepatic fibrosis, advanced fibrosis K74.02] and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Hepatic fibrosis, advanced fibrosis: Total Bilirubin & in Hepatic fibrosis, advanced fibrosis (K74.02: Albumin) (Bilirubin 0.2–1.2 mg/dL; Albumin >= 4.0 g/dL (K74.02)) and Fasting Lipase & in Hepatic fibrosis, advanced fibrosis (K74.02: Triglycerides).
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data
3 of 3 Free Questions RemainingAsk our AI Specialists anything about Hepatic fibrosis, advanced fibrosis
What Is Hepatic fibrosis, advanced fibrosis?
Physicians managing Hepatic fibrosis, advanced fibrosis (K74.02; Liver, Gallbladder & Pancreatic Health) utilize comprehensive hepatic panel [Hepatic fibrosis, advanced fibrosis K74.02] and objective Total Bilirubin & in Hepatic fibrosis, advanced fibrosis (K74.02: Albumin) targets (Bilirubin 0.2–1.2 mg/dL; Albumin >= 4.0 g/dL (K74.02)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Hepatic fibrosis, advanced fibrosis (ICD-10 K74.02) is driven by oxidative lipotoxicity [Hepatic fibrosis, advanced fibrosis K74.02]; specialists in Liver, Gallbladder & Pancreatic Health monitor Fasting Lipase & in Hepatic fibrosis, advanced fibrosis (K74.02: Triglycerides) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Hepatic fibrosis, advanced fibrosis (K74.02): unexplained fatigue, pruritus [Hepatic fibrosis, advanced fibrosis K74.02]
- • Secondary Hepatic fibrosis, advanced fibrosis clinical sign: epigastric pain, steatorrhea [Hepatic fibrosis, advanced fibrosis K74.02]
- • Symptom flares in Hepatic fibrosis, advanced fibrosis correlating with Total Bilirubin & in Hepatic fibrosis, advanced fibrosis (K74.02: Albumin) deviation outside Bilirubin 0.2–1.2 mg/dL; Albumin >= 4.0 g/dL (K74.02)
- • Functional liver & hepatology impact requiring comprehensive hepatic panel [Hepatic fibrosis, advanced fibrosis K74.02] evaluation (K74.02)
Hepatic fibrosis, advanced fibrosis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | K74.02 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Liver, Gallbladder & Pancreatic Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: Total Bilirubin & in Hepatic fibrosis, advanced fibrosis (K74.02: Albumin) | Bilirubin 0.2–1.2 mg/dL; Albumin >= 4.0 g/dL (K74.02) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipase & in Hepatic fibrosis, advanced fibrosis (K74.02: Triglycerides) | Normal enzymatic baseline (K74.02) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ALT, AST, Alkaline in Hepatic fibrosis, advanced fibrosis (K74.02: Phosphatase & GGT) | ALT < 25 U/L (men) / < 19 U/L (women) (K74.02) | Clinical Reference Target Range |
Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance
Check Drug Interactions →
FDA-Monographed Medications & Public Cash Price Reference for Hepatic fibrosis, advanced fibrosis
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Lidothol Es (Menthol 5%, Lidocaine 4%) Lidothol Es • RxCUI 1552201 | Amide Local Anesthetic | 76% | $0.8804 | $ 71.89 /mo |
| Ripretinib Qinlock • RxCUI 2369397 | Kinase Inhibitor | 93% | $3.1800 | $ 137.29 /mo |
| Sacituzumab Govitecan Trodelvy • RxCUI 2360534 | FDA Prescription Therapeutic Agent | 92% | $2.6800 | $ 117.04 /mo |
| Rolaids Advanced Antacid Anti-Gas Mixed Berry (Calcium Carbonate and Magnesium Hydroxide and Simethicone) Rolaids Advanced Antacid Anti-Gas Mixed Berry • RxCUI 1649510 | Blood Coagulation Factor | 78% | $2.6300 | $ 197.86 /mo |
| Dicloenac Sodium and Misoprostol Dicloenac Sodium and Misoprostol Generic • RxCUI RXN-804250273-2607 | Prostaglandin E1 Analog | 90% | $2.5300 | $ 110.96 /mo |
| Sotorasib Lumakras • RxCUI 2550719 | FDA Prescription Therapeutic Agent | 86% | $2.7100 | $ 118.26 /mo |
| Lidothol (Lidocaine and Menthol) Lidothol • RxCUI 1249758-B804250385 | Amide Local Anesthetic | 81% | $0.0989 | $ 15.62 /mo |
| Sonidegib Odomzo • RxCUI 1659921 | Hedgehog Pathway Inhibitor | 83% | $0.3900 | $ 24.30 /mo |
| Alocane Advanced Scar and Itch (Calendula Officinalis, Grindelia Robusta) Alocane Advanced Scar and Itch • RxCUI RXN-B68229409 | Over-the-Counter Clinical Monograph | 74% | $2.1000 | $ 159.70 /mo |
| Datopotamab Deruxtecan Datroway • RxCUI 2703040 | FDA Prescription Therapeutic Agent | 82% | $0.4300 | $ 25.92 /mo |
| Sensodyne Advanced Whitening Plus (Potassium Nitrate) Sensodyne Advanced Whitening Plus • RxCUI 1086243 | Over-the-Counter Clinical Monograph | 77% | $1.1300 | $ 89.86 /mo |
| Salicor (Triethanolamine Salicylate) Salicor • RxCUI 2722423 | FDA Prescription Therapeutic Agent | 87% | $3.4300 | $ 255.46 /mo |
| Rolaids Advanced Antacid Anti-Gas Wild Berry (Calcium Carbonate and Magnesium Hydroxide and Simethicone) Rolaids Advanced Antacid Anti-Gas Wild Berry • RxCUI 1649510-B411671041 | Blood Coagulation Factor | 84% | $3.4200 | $ 254.74 /mo |
| Lapatinib Tykerb • RxCUI 672149 | Kinase Inhibitor | 79% | $0.8100 | $ 41.30 /mo |
| Temsirolimus Torisel • RxCUI 722289 | FDA Prescription Therapeutic Agent | 80% | $3.4700 | $ 149.04 /mo |
| Megestrol Acetate Megace • RxCUI 860221 | Progestin | 79% | $0.2155 | $ 9.21 /mo |
Dr. Lin (AI PubMed Clinical Trial Lead)
Browse All PubMed Translations →
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Hepatic fibrosis, advanced fibrosis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Effect of L-carnitine on quality of life in covert liver encephalopathy: a Twenty-four weeks of L-carnitine supplementation was safe but ineffective in improving quality of life and liver function. The Korean journal of internal medicine • 2022-07-15 • Phase III Randomized Trial | N = 150 | 88/100 | PMID 35526858 ↗ |
| Can This Approach Help? Inside the Latest Research on Bimekizumab safety in moderate to severe plaque psoriasis skin flare-ups: Rates Rates of liver side effects (AEs) with bimekizumab were consistent through 2 years; incidences of transaminase elevations were similar to comparators during phase 3/3b controlled study periods. Journal of the American Academy of Dermatology • 2024-08-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38588819 ↗ |
| Can This Approach Help? Inside the Latest Research on Whey Protein Supplementation on Muscle Damage, liver Stress, and Inflammatory The results highlight whey protein's potential as a nutritional aid to promote recovery and physiological adaptation, possibly mediated by antioxidant and anti-inflammatory mechanisms. European journal of sport science • 2026-11-15 • Randomized Controlled Trial | N = 30 | 88/100 | PMID 42929456 ↗ |
| Managing Acute liver porphyria: Can Disease burden Make a Real Difference? (What New Research Reveals) Patients with AHP, regardless of annualized attack rates, have considerable disease burden that may partly be alleviated with givosiran. Orphanet journal of rare diseases • 2022-08-26 • Phase III Randomized Trial | N = 46 | 88/100 | PMID 36028858 ↗ |
| Can This Approach Help? Inside the Latest Research on Dipeptidyl peptidase-4 inhibitor, anagliptin, alters liver insulin clearance in Anagliptin affected HIC levels according to HIC baseline levels. Journal of diabetes investigation • 2021-10-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33751849 ↗ |
Zero-PHI Patient Support & Cohort Discussions
Hepatic fibrosis, advanced fibrosis Patient Community & “People Like Me” Threads
“People Like Me” Cohort Filter (Zero-PHI)
Filter Hepatic fibrosis, advanced fibrosis community threads and patient logs by age, biological sex, dosage, and treatment duration.
No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Hepatic fibrosis, advanced fibrosis.